PRMT5 and prostate cancer: A 2007 study by Teng et al may give a first element of response.51 In this study, Teng et al show that treatment of prostate cancer cells using the nucleolin octamer AS1411, leads to a nucleolin‐mediated redistribution of PRMT5 from the nucleus to the cytoplasm.